Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
An article from
Dive Brief
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
Published May 29, 2026
A micrograph of myeloma neoplasm in a bone marrow biopsy.
Bristol Myers details Phase 3 trial win for Pomalyst successor
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
New pill offers hope for patients with incurable blood cancer
Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
Mieloma multiplo, approvata la nuova terapia quadrupla AIFA: più efficacia e meno tossicità nelle cure di prima linea
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Mieloma multiplo, rimborsata nuova indicazione in prima linea per daratumumab
Mieloma multiplo: ecco la nuova indicazione di daratumumab | Libero Quotidiano.it
Mieloma multiplo: ecco la nuova indicazione di daratumumab - Il Quotidiano del Sud
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology…
Bristol Myers Squibb’s next-gen multiple myeloma drug mezigdomide cut the risk of disease progression or death for certain…
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of…
About 6,200 people every year in the UK are diagnosed with multiple myeloma
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech…
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
